

Homerton University Hospital NHS Foundation Trust  
Hackney College  
Defoe Building, Room 10  
50 Hoxton Street  
N1 6LP

Date 06<sup>th</sup> April 2016

Email: [foi@homerton.nhs.uk](mailto:foi@homerton.nhs.uk)

Dear Sir or Madam,

**Ref: FOI 2384**

Thank you for your recent Freedom of Information request regarding the number of patients diagnosed with leukaemia being treated at Homerton Hospital.

The Trust can provide the following information:

- 1. In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?**
- 2. Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?**
  - **Dasatinib (Sprycel)**
  - **Imatinib (Glivec)**
  - **Nilotinib (Tasigna)**
  - **Ponatinib (Iclusig)**
  - **Bosutinib (Bosulif)**
- 3. If possible, of these patients on a TKI, how many have had treatment with a previous TKI?**
- 4. In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?**
- 5. Of these patients how many are currently being treated with each of the following TKIs?**
  - **Dasatinib (Sprycel)**
  - **Imatinib (Glivec)**
  - **Nilotinib (Tasigna)**
  - **Ponatinib (Iclusig)**
  - **Bosutinib (Bosulif)**
  - **Other (i.e. not on a TKI)**

With regards to the above questions the Trust cannot provide this information as patients diagnosed with Leukaemia are referred directly to Bart's Health NHS Trust for treatment.

If you have any queries about this response please contact the information governance manager at [foi@homerton.nhs.uk](mailto:foi@homerton.nhs.uk), in the first instance. If following that, you still have any concerns, you may contact the Information Commissioner either by letter, FOI/EIR Complaints resolution, Wycliffe House, Water Lane, Wilmslow, Cheshire SM9 5AF, or by email [www.informationcommissioner.gov.uk](http://www.informationcommissioner.gov.uk) to take them further.

#### Copyright Statement

The material provided is subject to the HUHFT's copyright unless otherwise indicated. Unless expressly indicated on the material to the contrary, it may be reproduced free of charge in any format or medium, provided it is reproduced accurately and not used in a misleading manner. Where any of the copyright items are being re-published or copied to others, you must identify the source of the material and acknowledge the copyright status. Permission to reproduce material does not extend to any material accessed through the Publication Scheme that is the copyright of third parties. You must obtain authorisation to reproduce such material from the copyright holders concerned.

Yours sincerely

Mohamed Uddin  
FoI Administrator

Mike Dunne  
Information Governance Manager